GlassScriptPhysician profile
Reem Beckerly
NPI 1437314630
$3,476.18
in general payments reported to CMS, 2019-2025
21 companies · $69.99 in 2025
The $69.99 reported for 2025 was less than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.47 · 2020: $564 · 2021: $1,106 · 2022: $1,118 · 2023: $402 · 2024: $194 · 2025: $69.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.50 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $979.48 | 2019-2024 | |
| Harmony Biosciences LLC | $621.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $383.39 | 2020-2024 | Nucala |
| Grifols USA, LLC | $302.20 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $272.06 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.38 | 2020-2022 | |
| Inspire Medical Systems, INC. | $126.37 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $82.58 | 2021-2022 | |
| Mylan Specialty L.P. | $75.92 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.84 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.13 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $57.13 | 2021-2022 | |
| United Therapeutics Corporation | $46.35 | 2021 | |
| Advanced Respiratory, INC | $45.01 | 2021 | |
| Electromed, INC. | $43.33 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $41.16 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $22.44 | 2022 | |
| Baxter Healthcare | $21.45 | 2022 | |
| Amgen INC. | $20.70 | 2022 | |
| Novo Nordisk INC | $17.78 | 2022 | |
| Philips North America LLC | $16.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Beckerly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.